ATE255910T1 - Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren - Google Patents
Zellmodulierende konjugate aus elementen aus spezifischen bindungspaarenInfo
- Publication number
- ATE255910T1 ATE255910T1 AT97917902T AT97917902T ATE255910T1 AT E255910 T1 ATE255910 T1 AT E255910T1 AT 97917902 T AT97917902 T AT 97917902T AT 97917902 T AT97917902 T AT 97917902T AT E255910 T1 ATE255910 T1 AT E255910T1
- Authority
- AT
- Austria
- Prior art keywords
- conjugates
- elements
- specific bonding
- cell modulating
- bonding pairs
- Prior art date
Links
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 abstract 1
- 125000003169 alpha-Gal epitope group Chemical group [C@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O)O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63038396A | 1996-04-10 | 1996-04-10 | |
| PCT/US1997/005842 WO1997037690A2 (en) | 1996-04-10 | 1997-04-09 | Cytomodulating conjugates of members of specific binding pairs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE255910T1 true ATE255910T1 (de) | 2003-12-15 |
Family
ID=24526956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97917902T ATE255910T1 (de) | 1996-04-10 | 1997-04-09 | Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060002891A1 (de) |
| EP (1) | EP0833666B1 (de) |
| JP (1) | JPH10511989A (de) |
| AT (1) | ATE255910T1 (de) |
| AU (1) | AU2610097A (de) |
| CA (1) | CA2218737C (de) |
| DE (1) | DE69726674T2 (de) |
| ES (1) | ES2210514T3 (de) |
| WO (1) | WO1997037690A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7298398A (en) * | 1996-11-19 | 1998-06-10 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
| WO1999024077A2 (en) * | 1997-11-10 | 1999-05-20 | Cytimmune Sciences, Inc. | Compositions and methods for targeted delivery of biologically-active factors |
| WO2001032207A1 (en) * | 1998-10-30 | 2001-05-10 | United States Army Medical Research And Materiel Command | Methods for conferring active/passive immunotherapy |
| US7645743B2 (en) | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| CA2328356A1 (en) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
| CN1441676B (zh) | 2000-03-31 | 2012-08-22 | 普渡研究基金会 | 用配体-免疫原缀合物治疗的方法 |
| CN101979095A (zh) | 2001-05-02 | 2011-02-23 | 普渡研究基金会 | 巨噬细胞介导的疾病的治疗和诊断 |
| EP2168598A1 (de) * | 2001-09-28 | 2010-03-31 | Purdue Research Foundation | Verfahren zur Behandlung mit Ligand-Immunogen-Konjugaten |
| EP1443963B1 (de) | 2001-10-22 | 2014-05-21 | The Scripps Research Institute | Antikörper-targeting-verbindungen |
| US8043603B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| WO2004110250A2 (en) | 2003-05-30 | 2004-12-23 | Purdue Research Foundation | Diagnostic method for atherosclerosis |
| RU2007128036A (ru) * | 2004-12-23 | 2009-01-27 | Пердью Рисерч Фаундейшн (Us) | Способ получения изображения позитронно-эмиссионной томографией |
| EP1904183B1 (de) | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmazeutische Zusammensetzung zur Behandlung von Arthrose |
| US8795633B2 (en) | 2005-09-23 | 2014-08-05 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
| US8168164B2 (en) | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
| JP2010509570A (ja) | 2006-11-03 | 2010-03-25 | パーデュー・リサーチ・ファウンデーション | エクスビボフローサイトメトリーの方法および装置 |
| US8586595B2 (en) | 2007-02-07 | 2013-11-19 | Purdue Research Foundation | Positron emission tomography imaging method |
| WO2008148001A2 (en) | 2007-05-25 | 2008-12-04 | Purdue Research Foundation | Method of imaging localized infections |
| KR101098581B1 (ko) * | 2009-01-09 | 2011-12-26 | 서울대학교산학협력단 | Ａｂｈ 항원을 이용한 염증질환 개선용 조성물 |
| CN102459298A (zh) | 2009-05-05 | 2012-05-16 | 阿尔特姆恩科技责任有限公司 | 化学可编程免疫 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314988A (en) * | 1979-10-31 | 1982-02-09 | Baker Instruments Corp. | Folic acid derivatives and process for preparation |
| AU573529B2 (en) * | 1982-05-12 | 1988-06-16 | President And Fellows Of Harvard College | Hybrid proteins |
| US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4971792A (en) * | 1987-03-27 | 1990-11-20 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens |
| US4946945A (en) * | 1987-06-23 | 1990-08-07 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
| DE3880766D1 (de) * | 1987-09-02 | 1993-06-09 | Ciba Geigy Ag | Konjugate von interferon alpha mit immunglobulinen. |
| DK8189A (da) * | 1988-01-12 | 1989-07-13 | Bunge Australia | Antigen-antistof-konjugater, deres fremstilling og anvendelse |
| KR900005995A (ko) * | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| DE68926380T2 (de) * | 1988-11-14 | 1996-09-12 | Kanegafuchi Chemical Ind | Sphärische Vinylchloridharzgranulate und Verfahren zu ihrer Herstellung |
| KR920703114A (ko) * | 1989-07-14 | 1992-12-17 | 원본미기재 | 접합체 백신을 위한 시토킨 및 호르몬 운반체 |
| EP0457875A4 (en) * | 1989-11-13 | 1993-03-03 | Xoma Corporation | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
| EP0547163B1 (de) * | 1990-08-29 | 2002-02-06 | Centre Hospitalier Regional De Nantes | An stabile proteinkernstruktur gebundene proteinpolyliganden |
| JP3105629B2 (ja) * | 1991-04-23 | 2000-11-06 | サングスタット メディカル コーポレイション | 特異的結合ペアのメンバーの細胞活性調節接合体 |
| US5547668A (en) * | 1995-05-05 | 1996-08-20 | The Board Of Trustees Of The University Of Illinois | Conjugates of folate anti-effector cell antibodies |
-
1997
- 1997-04-09 AT AT97917902T patent/ATE255910T1/de not_active IP Right Cessation
- 1997-04-09 AU AU26100/97A patent/AU2610097A/en not_active Abandoned
- 1997-04-09 DE DE69726674T patent/DE69726674T2/de not_active Expired - Fee Related
- 1997-04-09 WO PCT/US1997/005842 patent/WO1997037690A2/en not_active Ceased
- 1997-04-09 ES ES97917902T patent/ES2210514T3/es not_active Expired - Lifetime
- 1997-04-09 EP EP97917902A patent/EP0833666B1/de not_active Expired - Lifetime
- 1997-04-09 CA CA002218737A patent/CA2218737C/en not_active Expired - Fee Related
- 1997-04-09 JP JP9536451A patent/JPH10511989A/ja not_active Ceased
-
2005
- 2005-09-13 US US11/180,409 patent/US20060002891A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2218737A1 (en) | 1997-10-16 |
| EP0833666A3 (de) | 1998-07-08 |
| DE69726674T2 (de) | 2004-10-21 |
| US20060002891A1 (en) | 2006-01-05 |
| EP0833666A2 (de) | 1998-04-08 |
| CA2218737C (en) | 2003-12-16 |
| JPH10511989A (ja) | 1998-11-17 |
| AU2610097A (en) | 1997-10-29 |
| ES2210514T3 (es) | 2004-07-01 |
| EP0833666B1 (de) | 2003-12-10 |
| WO1997037690A2 (en) | 1997-10-16 |
| WO1997037690A3 (en) | 1998-03-05 |
| DE69726674D1 (de) | 2004-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE255910T1 (de) | Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren | |
| EP0510949A3 (de) | Zytomodulierte Konjugate enthaltend spezifische Bindungspaargliedern | |
| PT888384E (pt) | Polipeptido de fusao para influenciar as interaccoes entre proteinas | |
| NO963018D0 (no) | CTLA4-mutantmolekyler og anvendelser derav | |
| TR199900113A3 (tr) | Esnek hücreli malzeme, birlesimi ve hazirlanmasi için usul. | |
| DE69528894D1 (de) | Bifunktionelles protein, herstellung und verwendung | |
| DE60113393D1 (de) | Klebstoffzusammensetzungen aus pflanzlichem protein | |
| DE3683785D1 (de) | Rueckseitenmaterial fuer einen ultraschallwandler. | |
| FI830897A7 (fi) | Menetelmä uusien konjugaattien valmistamiseksi, joissa entsyymi ja vasta-aine ovat sitoutuneet kovalekovalenttisella sidoksella. | |
| ATE277624T1 (de) | Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen | |
| BR9604825A (pt) | Citostáticos modificados por carboidratos | |
| EP0604038A3 (de) | Plastifizierte Polyetherimide-Klebstoffmischungen. | |
| ES557103A0 (es) | Un procedimiento para preparar una proteina hibrida | |
| TR200100607T2 (tr) | Bellek efektör T-hücrelerinin modülasyonu için yöntem ve bileşimler | |
| DE60017141D1 (de) | Replikationskompetente anti-tumor vektoren | |
| TR200003323T2 (tr) | Geniş-tesir sahalı mantar önleyiciler olarak suda eriyebilir azoller | |
| WO2000003724A1 (en) | Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient | |
| NO991867L (no) | Biaromatiske forbindelser bundet via et heteroetynylenradikal, og farmas°ytiske og kosmetiske sammensetninger inneholdende dem | |
| DE60043070D1 (de) | Proteine-abgabe durch polare epithelzellen schichte | |
| DK0745122T3 (da) | Galninreceptor, nukleinsyrer, transformerede celler og anvendelser heraf | |
| DK0983361T3 (da) | Bakterielle pheromoner og anvendelser deraf | |
| FI880582A0 (fi) | Paperinvalmistuksessa käytettävät uudet valmisteet | |
| DE58903624D1 (de) | Strahlenhaertende, thermoaktivierbare klebstoffmischungen. | |
| NO883886L (no) | Flammehemmende ethylencopolymermateriale. | |
| ES2170161T3 (es) | Nuevos conjugados de principios activos y proteinas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |